Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis
NCT01877694
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
217
Enrollment
INDUSTRY
Sponsor class
Conditions
Bacterial Conjunctivitis
Interventions
DRUG:
Auriclosene Solution 0.3%
DRUG:
Auriclosene Vehicle
Sponsor
NovaBay Pharmaceuticals, Inc.